Brief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
14/10/2026 02:36
BRIEF-Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix Oct 14 (Reuters) - ReNerve Ltd RNV.AX:
POSITIVE FDA FEEDBACK ON NERVALIGN NERVE GUIDE MATRIX
RECEIVES POSITIVE FDA FEEDBACK FOR NERVALIGN NERVE GUIDE MATRIX
Further company coverage: RNV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Renerve
See all newsBrief: Renerve Says Positive FDA Feedback On Nervalign Nerve Guide Matrix
Brief: Renerve And Rmit Awarded A$499K Grant
Brief: ReNerve Posts Full-Year Loss Attributable Of A$5.6 Million
Brief: ReNerve Says Nervalign Nerve Cuff Receives CDSCO Marketing Approval In India
Australia's ReNerve rises on securing up to A$5 million funding facility